Setor K Kunutsor1, Tanefa A Apekey2, Hassan Khan3. 1. Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, United Kingdom. Electronic address: skk31@cantab.net. 2. Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds, Charles Thackrah Building, 101 Clarendon Road, Leeds LS2 9LJ, United Kingdom. 3. Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, United Kingdom.
Abstract
BACKGROUND: Gamma glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), commonly used markers of liver dysfunction, have been implicated with risk of cardiovascular disease (CVD). However, the strength and consistency of their associations in the general population have not been reliably quantified. METHODS: We synthesized available prospective epidemiological data on the associations of baseline levels of GGT, ALT, AST, and ALP with CVD [composite CVD, coronary heart disease (CHD), or stroke outcomes]. Relevant studies were identified in a literature search of MEDLINE, EMBASE, and Web of Science up to December 2013. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random effects models. RESULTS: Twenty-nine unique cohort studies with aggregate data on over 1.23 million participants and 20,406 cardiovascular outcomes were included. The pooled fully adjusted RRs (95% CIs) for CVD were 1.23 (1.16-1.29) and 1.08 (1.03-1.14) per 1-standard deviation change in log baseline levels of GGT and ALP levels respectively. There was no evidence of an association of ALT or AST with CVD, however, ALT was somewhat inversely associated with CHD 0.95 (0.90-1.00) and positively associated with stroke 1.01 (1.00-1.02) in stratified analysis. Tests for nonlinearity were suggestive of linear relationships of GGT and ALP levels with CVD risk. CONCLUSIONS: Baseline levels of GGT and ALP are each positively associated with CVD risk and in a log-linear fashion. There may be variations in the associations of ALT with cause-specific cardiovascular endpoints, findings which require further investigation.
BACKGROUND:Gamma glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), commonly used markers of liver dysfunction, have been implicated with risk of cardiovascular disease (CVD). However, the strength and consistency of their associations in the general population have not been reliably quantified. METHODS: We synthesized available prospective epidemiological data on the associations of baseline levels of GGT, ALT, AST, and ALP with CVD [composite CVD, coronary heart disease (CHD), or stroke outcomes]. Relevant studies were identified in a literature search of MEDLINE, EMBASE, and Web of Science up to December 2013. Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated using random effects models. RESULTS: Twenty-nine unique cohort studies with aggregate data on over 1.23 million participants and 20,406 cardiovascular outcomes were included. The pooled fully adjusted RRs (95% CIs) for CVD were 1.23 (1.16-1.29) and 1.08 (1.03-1.14) per 1-standard deviation change in log baseline levels of GGT and ALP levels respectively. There was no evidence of an association of ALT or AST with CVD, however, ALT was somewhat inversely associated with CHD 0.95 (0.90-1.00) and positively associated with stroke 1.01 (1.00-1.02) in stratified analysis. Tests for nonlinearity were suggestive of linear relationships of GGT and ALP levels with CVD risk. CONCLUSIONS: Baseline levels of GGT and ALP are each positively associated with CVD risk and in a log-linear fashion. There may be variations in the associations of ALT with cause-specific cardiovascular endpoints, findings which require further investigation.
Authors: Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi; Antonio Picardi Journal: J Gerontol A Biol Sci Med Sci Date: 2018-06-14 Impact factor: 6.053
Authors: Martin Janicko; Sylvia Drazilova; Daniel Pella; Jan Fedacko; Peter Jarcuska Journal: World J Gastroenterol Date: 2016-07-21 Impact factor: 5.742
Authors: Nonhlakanipho F Sangweni; Phiwayinkosi V Dludla; Rebamang A Mosa; Abidemi P Kappo; Andy Opoku; Christo J F Muller; Rabia Johnson Journal: Heart Fail Rev Date: 2019-01 Impact factor: 4.214
Authors: James L Dorling; Eric Ravussin; Leanne M Redman; Manju Bhapkar; Kim M Huffman; Susan B Racette; Sai K Das; John W Apolzan; William E Kraus; Christoph Höchsmann; Corby K Martin Journal: Eur J Nutr Date: 2020-08-14 Impact factor: 5.614
Authors: Esmée M Bijnens; Catherine Derom; Evert Thiery; Dries S Martens; Ruth J F Loos; Steven Weyers; Tim S Nawrot Journal: Sci Rep Date: 2021-06-11 Impact factor: 4.379